On 1 April 2020, the FAMHP took steps to avoid a shortage of medicinal products. Some of these measures are to be further extended by one month, while others have been lifted.
Stocks of medicinal products used to treat COVID-19 patients (such as narcotics and muscle relaxants for patients on ventilators) are closely monitored by the FAMHP.
The FAMHP has drawn up a list of medicinal products and raw materials used in the treatment of COVID-19, for which emergency measures have been in place since 1 April 2020. These measures have since been refined and extended. The new decision further extends certain measures by one month. These include measures relating to the export of medicinal products, quotas for wholesalers and optimal distribution between hospitals. Other measures, in particular the export notification requirement and the reporting of excess stock, have been abolished.
Thanks to these measures and their extension, solutions and alternatives for all medicinal products necessary for the treatment of COVID-19 patients in Belgium currently exist and will exist in the near future.
Revision of the list of medicinal products
The list of medicinal products and raw materials concerned has also been revised. The situation is constantly evolving and the list has also been adapted accordingly.